Skip to content
WELCOME10 — 10% OFF YOUR FIRST ORDER  ·  FREE SHIPPING OVER $300 CAD  ·  COA ON REQUEST
Research Comparison

Cagrilintide vs IGF-1 LR3

Cagrilintide and IGF-1 LR3 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.

Shared research areas:Metabolic
ClassLipidated 37-residue amylin analogue, Cys2–Cys7 disulfide, C-terminal prolinamideRecombinant 83-residue protein analogue of IGF-1
Molecular weightNot specifiedNot specified
CAS numberNot assigned / not specifiedNot assigned / not specified
Purity spec≥99%≥99%
Research areasMetabolicHormonal & Endocrine, Metabolic, Musculoskeletal
Primary diluentBacteriostatic water (0.9% benzyl alcohol)Dilute acetic acid (0.1 M) or 10 mM HCl — required for initial dissolution
Working windowCommonly worked with for 3–4 weeks at 2–8 °C.Short: commonly worked with within 1–2 weeks at 2–8 °C, or frozen in single-use aliquots.
Lead degradation routeFibrillation — the failure mode specific to this molecular class, and the one its whole design addresses.Denaturation and aggregation — the dominant failure mode, and one that has no equivalent in short unstructured peptides.
Freeze–thawAvoid freezing reconstituted material. For an amylin analogue the freeze–thaw concern is not only interfacial aggregation but nucleation of the fibril pathway the molecule was engineered to resist — and fibril formation, once seeded, does not reverse on rewarming.Single-use aliquots are the standard practice, and here it genuinely matters. IGF-1 LR3 has tertiary structure to lose — unlike the unstructured short peptides in this catalogue, it can denature, and denaturation is not reversible on rewarming.
Light sensitivityNo specific light requirement beyond normal practice.No specific light requirement beyond normal practice.

How they actually differ

Comparing the two: Cagrilintide is lipidated 37-residue amylin analogue, cys2–cys7 disulfide, c-terminal prolinamide, while IGF-1 LR3 is recombinant 83-residue protein analogue of igf-1 — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus dilute acetic acid (0.1 m) or 10 mm hcl — required for initial dissolution); their leading degradation routes differ (fibrillation for Cagrilintide, denaturation and aggregation for IGF-1 LR3), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.

Cagrilintide — origin

Cagrilintide is an engineered analogue of human amylin (IAPP), the 37-residue hormone co-secreted with insulin from pancreatic beta cells. Its design problem was unusually specific: native amylin is strongly amyloidogenic, readily collapsing from helix into the beta-sheet conformation that seeds fibrils, which is what made a long-acting amylin drug difficult for decades. Cagrilintide carries six substitutions relative to human amylin (14E, 17R, 25P, 28P, 29P, 37P) — roughly 84% sequence homology — plus N-terminal acylation with a C20 fatty diacid through a gamma-glutamate linker.

IGF-1 LR3 — origin

IGF-1 LR3 is an engineered analogue carrying two changes to native IGF-1: an arginine substitution at position 3 and a 13-residue N-terminal extension. The Arg3 substitution is the functional one — it drastically reduces binding to IGF binding proteins, which normally sequester the great majority of circulating IGF-1. The result is a molecule that stays free rather than bound.

Cagrilintide research themes

Amylin receptor pharmacology

Cagrilintide binds the calcitonin receptor and all three amylin receptors (AMY1, AMY2, AMY3), which is why the literature sometimes classes it as a dual amylin and calcitonin receptor agonist.

Amyloid-resistant peptide design

A worked example of engineering a fibril-prone hormone into a stable long-acting analogue — salt-bridge helix stabilisation plus beta-sheet-breaking prolines.

Protraction by acylation

The C20 diacid extends the half-life from minutes, for the short-acting analogue pramlintide, to roughly a week.

Combination with incretin agonists

The most-studied context: co-administration with semaglutide, investigated in the REDEFINE trial programme.

IGF-1 LR3 research themes

IGFBP evasion

The Arg3 substitution reduces binding-protein affinity, which is the entire design rationale.

Cell proliferation

Widely used in cell-culture research as a growth-factor supplement.

Satellite cell activation

Studied in muscle-biology research models.

PI3K/Akt signalling

The canonical downstream pathway examined in IGF-1 receptor research.

Cagrilintide handling

  • Never shake. Swirl gently and allow the cake to dissolve in its own time.
  • Do not freeze reconstituted solution.
  • Add diluent down the vial wall rather than directly onto the cake.
  • Treat visible particulate or a settling precipitate as a rejected vial — for an amylin analogue this is the observable end of the fibrillation pathway, not a cosmetic issue.

IGF-1 LR3 handling

  • Dissolve in dilute acetic acid or dilute HCl FIRST; do not attempt direct dissolution in water or PBS.
  • Add carrier protein (e.g. 0.1% BSA) for storage of dilute solutions to prevent adsorptive loss.
  • Prepare single-use aliquots — freeze–thaw denaturation is irreversible.
  • Do not vortex; agitation denatures folded proteins at the air–liquid interface.

Both third-party tested

Every Popular Peptides batch of Cagrilintide and IGF-1 LR3 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.

Verify a batchPublished COAsHow we test

Cagrilintide reference

Full Cagrilintide reference Cagrilintide storage Cagrilintide reconstitution Cagrilintide calculatorCagrilintide product details

IGF-1 LR3 reference

Full IGF-1 LR3 reference IGF-1 LR3 storage IGF-1 LR3 reconstitution IGF-1 LR3 calculatorIGF-1 LR3 product details

Related comparisons

5-Amino-1MQ vs Cagrilintide5-Amino-1MQ vs IGF-1 LR3BPC-157 vs IGF-1 LR3Cagrilintide vs CJC-1295 (No DAC)Cagrilintide vs CJC-1295 + IpamorelinCagrilintide vs GLP-2/TirzCagrilintide vs GLP-3/RTCagrilintide vs Ipamorelin

Cagrilintide and IGF-1 LR3 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.